Newtree Co., Ltd.

Biocare Co., Ltd.

Aat Costech Co., Ltd.

Jae Youn Chung

Jeong Hwan Kim

Jae-Kwan Hwang

Do Un Kim

Heechul Chung

Hae Ji Lee

Jae-Young Lee

Do Hun Kim

Jae Young Lee

Jeong-Hwan Kim

Jae Kwan Hwang

Jong-hee Sohn

Hee Chul Chung

Kyu-Lee Han

Yu-Mi Cho

Gyu Hoi Kim

Hyun In Oh

Jae-Seok Shim

Ah-Jin Kim

Jeong-Han Choo

The present invention relates to a new use of lignan-type compounds or an extract of nutmeg or aril of nutmeg comprising the same. More particularly, the present invention relates to a composition for skin whitening comprising a lignan-type compound or an extract of nutmeg or aril of nutmeg comprising the same. Because the lignan compound represented by Chemical Formulas 1 to 3 or the extract of nutmeg or aril of nutmeg has superior skin whitening activity by inhibiting melanin production and tyrosinase activity, it can be used for the preparation of a cosmetic composition, food composition or pharmaceutical composition for skin whitening.

Use of lignan-type compounds or extract of nutmeg or aril of nutmeg comprising the same

The present invention relates to a novel use of lignan compounds, which are isolated and purified from nutmeg or the aril of nutmeg for anti-wrinkle, and more particularly, the present invention relates to a novel use for anti-wrinkle of an extract of the nutmeg or an extract of the aril of the nutmeg, fragrin A, austobailignan 7, licarin E, and macelignan. The extracts and lignan compounds of the present invention have activities in suppressing collagen degradation enzyme-1 (MMP-I, matrix metalloprotei-nase-1) and formation of new collagen (type-1 procollagen), thereby having effect on inhibitng wrinkle caused by photoaging. Accordingly, the extracts and lignan compounds of the present invention may be useful for preventing or treating wrinkle caused by photoaging.

Use of lignan compound for anti-wrinkle treatment

Disclosed is a method for treating PPAR (peroxisome proliferator activated receptor)-mediated diseases, such as diabetes mellitus, which includes administering to a subject an effective amount of macelignan represented by the following Formula (I): or a pharmaceutically acceptable salt thereof.

Method for treating conditions mediated by PPAR using macelignan

Growing community of inventors

Gyeonggi-do, South Korea

Jae Youn Chung